We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Access Pharmaceuticals has announced that its product for the treatment
of canker sores, Aphthasol, has received marketing approval in 10 European Union
countries following completion of the Mutual Recognition Procedure (MRP).
Experts from the World Health Organisation and the Disease Control Department
want Thailand to hold joint trials of a human vaccine against the H5N1 strain
of avian influenza.
Paras Pharmaceuticals, popular for its brands like
Moov, Krack, Stopache, Itchguard and D-Cold, has decided to expand its manufacturing
capacity by setting up a new formulations and cosmetics manufacturing facility
at Baddi in Himachal Pradesh.
South African generics maker Aspen Pharmacare claims that it has
won the largest share of the long-awaited government supply contract for HIV/AIDS
generics.
Brazilian drug regulator Anvisa has begun a 30-day public consultation
on Decree 5.348, which authorises pharmacists to split the contents of drug
packets according to a consumer's prescribed dose.
Russian generic drugmaker Nizpharm has announced that Latvian state
health authorities have certified the company's manufacturing units as in line
with European Union GMP principles.
Israeli generics major Teva is to invest US$100mn on a new manufacturing
unit in northeastern Hungary, which is expected to manufacture active ingredients
and employ about 100 staff.